GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Total Equity

Diamyd Medical AB (FRA:DMN) Total Equity : €9.92 Mil (As of Feb. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Total Equity?

Diamyd Medical AB's total equity for the quarter that ended in Feb. 2025 was €9.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Diamyd Medical AB Total Equity Historical Data

The historical data trend for Diamyd Medical AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Total Equity Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.03 18.54 20.39 14.34 12.74

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.11 16.82 12.74 13.48 9.92

Diamyd Medical AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Diamyd Medical AB's Total Equity for the fiscal year that ended in Aug. 2024 is calculated as

Total Equity=Total Assets(Q: Aug. 2024 )-Total Liabilities(Q: Aug. 2024 )
=18.946-6.208
=12.74

Diamyd Medical AB's Total Equity for the quarter that ended in Feb. 2025 is calculated as

Total Equity=Total Assets(Q: Feb. 2025 )-Total Liabilities(Q: Feb. 2025 )
=16.087-6.168
=9.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Total Equity Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Total Equity
Comparable Companies
OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE OSTO:XSPRAY OSTO:FLUO OSTO:IBT B OSTO:GENO OSTO:IRLAB A OSTO:EGTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
DYMDF:USA DMYD B:Sweden
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.